scholarly journals Tear N ‐glycomics in vernal and atopic keratoconjunctivitis

Allergy ◽  
2021 ◽  
Author(s):  
Angela Messina ◽  
Angelo Palmigiano ◽  
Claudia Tosto ◽  
Donata Agata Romeo ◽  
Luisa Sturiale ◽  
...  
Keyword(s):  
Atopic Keratoconjunctivitis

Management of advanced ocular surface disease in patients with severe atopic keratoconjunctivitis

2019 ◽  
Vol 17 (2) ◽  
pp. 303-309 ◽  
Author(s):  
Sayena Jabbehdari ◽  
Taylor W. Starnes ◽  
Khaliq H. Kurji ◽  
Medi Eslani ◽  
Maria S. Cortina ◽  
...  
Keyword(s):  
Ocular Surface ◽  
Ocular Surface Disease ◽  
Atopic Keratoconjunctivitis

Association between atopic keratoconjunctivitis and the risk of keratoconus

2020 ◽  
Author(s):  
Shih‐Feng Weng ◽  
Ren‐Long Jan ◽  
Jhi‐Joung Wang ◽  
Sung‐Huei Tseng ◽  
Yuh‐Shin Chang
Keyword(s):  
Atopic Keratoconjunctivitis

Clinical Features of Atopic Keratoconjunctivitis

Ophthalmology ◽  
1991 ◽  
Vol 98 (2) ◽  
pp. 150-158 ◽  
Author(s):  
Stephen J. Tuft ◽  
D. Michael Kemeny ◽  
John K.G. Dart ◽  
Roger J. Buckley
Keyword(s):  
Clinical Features ◽  
Atopic Keratoconjunctivitis

scholarly journals Clinical Usefulness of Monitoring Expression Levels ofCCL24(Eotaxin-2) mRNA on the Ocular Surface in Patients with Vernal Keratoconjunctivitis and Atopic Keratoconjunctivitis

2016 ◽  
Vol 2016 ◽  
pp. 1-5 ◽  
Author(s):  
Yukiko Shiraki ◽  
Jun Shoji ◽  
Noriko Inada
Keyword(s):  
Mrna Expression ◽  
Ocular Surface ◽  
Clinical Score ◽  
Clinical Severity ◽  
Vernal Keratoconjunctivitis ◽  
Control Group ◽  
Expression Levels ◽  
Atopic Keratoconjunctivitis ◽  
Clinical Scores ◽  
Mrna Expression Levels

Purpose. This study aimed to evaluate the clinical efficacy of using expression levels ofCCL24(eotaxin-2) mRNA on the ocular surface as a biomarker in patients with vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC).Methods. Eighteen patients with VKC or AKC (VKC/AKC group) and 12 control subjects (control group) were enrolled in this study. The VKC/AKC clinical score was determined by objective findings in patients by using the 5-5-5 exacerbation grading scale. All subjects underwent modified impression cytology and specimens were obtained from the upper tarsal conjunctiva. Expression levels ofCCL24(eotaxin-2) mRNA on the ocular surface were determined using real-time reverse transcription polymerase chain reaction.Results. The VKC group was divided into two subgroups, depending on the clinical score: the active stage subgroup with 100 points or more of clinical scores and the stable stage subgroup with 100 points or less.CCL24(eotaxin-2) mRNA expression levels in the active VKC/AKC stage subgroup were significantly higher than those in the stable VKC/AKC subgroup and the control group. Clinical scores correlated significantly withCCL24(eotaxin-2) mRNA expression levels in the VKC group.Conclusions.CCL24(eotaxin-2) mRNA expression levels on the ocular surface are a useful biomarker for clinical severity of VKC/AKC.

Pharmacotherapeutic management of atopic keratoconjunctivitis

2020 ◽  
Vol 21 (14) ◽  
pp. 1761-1769
Author(s):  
Ibtesham T Hossain ◽  
Priyanka Sanghi ◽  
Bita Manzouri
Keyword(s):  
Atopic Keratoconjunctivitis
Sign in / Sign up

Export Citation Format

Share Document